vs
Side-by-side financial comparison of AMN HEALTHCARE SERVICES INC (AMN) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.4B, roughly 1.1× AMN HEALTHCARE SERVICES INC). Organon & Co. runs the higher net margin — 10.0% vs 4.5%, a 5.5% gap on every dollar of revenue. On growth, AMN HEALTHCARE SERVICES INC posted the faster year-over-year revenue change (100.0% vs -3.5%). Over the past eight quarters, AMN HEALTHCARE SERVICES INC's revenue compounded faster (36.4% CAGR vs -4.7%).
AMN Healthcare Services Inc. is a leading US healthcare sector workforce solutions and staffing provider. It offers temporary and permanent placement for nurses, physicians, allied health and other clinical/non-clinical staff, plus workforce management tools and consulting for hospitals, clinics and other medical facilities.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
AMN vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.5B |
| Net Profit | $62.2M | $146.0M |
| Gross Margin | 26.8% | 53.6% |
| Operating Margin | 8.5% | — |
| Net Margin | 4.5% | 10.0% |
| Revenue YoY | 100.0% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $1.59 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | $1.5B | ||
| Q4 25 | $748.2M | $1.5B | ||
| Q3 25 | $634.5M | $1.6B | ||
| Q2 25 | $658.2M | $1.6B | ||
| Q1 25 | $689.5M | $1.5B | ||
| Q4 24 | $734.7M | $1.6B | ||
| Q3 24 | $687.5M | $1.6B | ||
| Q2 24 | $740.7M | $1.6B |
| Q1 26 | $62.2M | $146.0M | ||
| Q4 25 | $-7.7M | $-205.0M | ||
| Q3 25 | $29.3M | $160.0M | ||
| Q2 25 | $-116.2M | $145.0M | ||
| Q1 25 | $-1.1M | $87.0M | ||
| Q4 24 | $-187.5M | $109.0M | ||
| Q3 24 | $7.0M | $359.0M | ||
| Q2 24 | $16.2M | $195.0M |
| Q1 26 | 26.8% | 53.6% | ||
| Q4 25 | 26.1% | 49.2% | ||
| Q3 25 | 29.1% | 53.5% | ||
| Q2 25 | 29.8% | 54.8% | ||
| Q1 25 | 28.7% | 55.6% | ||
| Q4 24 | 29.8% | 56.3% | ||
| Q3 24 | 31.0% | 58.3% | ||
| Q2 24 | 31.0% | 58.4% |
| Q1 26 | 8.5% | — | ||
| Q4 25 | 1.1% | -9.8% | ||
| Q3 25 | 7.5% | 15.2% | ||
| Q2 25 | -18.8% | 14.4% | ||
| Q1 25 | 1.8% | 6.7% | ||
| Q4 24 | -27.6% | 8.1% | ||
| Q3 24 | 3.2% | 13.1% | ||
| Q2 24 | 5.1% | 14.6% |
| Q1 26 | 4.5% | 10.0% | ||
| Q4 25 | -1.0% | -13.6% | ||
| Q3 25 | 4.6% | 10.0% | ||
| Q2 25 | -17.7% | 9.1% | ||
| Q1 25 | -0.2% | 5.8% | ||
| Q4 24 | -25.5% | 6.8% | ||
| Q3 24 | 1.0% | 22.7% | ||
| Q2 24 | 2.2% | 12.1% |
| Q1 26 | $1.59 | $0.55 | ||
| Q4 25 | $-0.19 | $-0.78 | ||
| Q3 25 | $0.76 | $0.61 | ||
| Q2 25 | $-3.02 | $0.56 | ||
| Q1 25 | $-0.03 | $0.33 | ||
| Q4 24 | $-4.90 | $0.42 | ||
| Q3 24 | $0.18 | $1.38 | ||
| Q2 24 | $0.42 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $560.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $2.6B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $560.7M | — | ||
| Q4 25 | $34.0M | $574.0M | ||
| Q3 25 | $52.6M | $672.0M | ||
| Q2 25 | $41.5M | $599.0M | ||
| Q1 25 | $55.8M | $547.0M | ||
| Q4 24 | $10.6M | $675.0M | ||
| Q3 24 | $30.6M | $763.0M | ||
| Q2 24 | $48.0M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $767.1M | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | $1.1B | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $642.1M | $752.0M | ||
| Q3 25 | $644.4M | $906.0M | ||
| Q2 25 | $607.6M | $733.0M | ||
| Q1 25 | $715.1M | $542.0M | ||
| Q4 24 | $706.6M | $472.0M | ||
| Q3 24 | $890.7M | $493.0M | ||
| Q2 24 | $876.9M | $144.0M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.1B | $12.9B | ||
| Q3 25 | $2.1B | $13.6B | ||
| Q2 25 | $2.2B | $13.5B | ||
| Q1 25 | $2.4B | $13.2B | ||
| Q4 24 | $2.4B | $13.1B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.8B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | 1.49× | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $562.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 9.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $562.5M | — | ||
| Q4 25 | $75.6M | $141.0M | ||
| Q3 25 | $22.7M | $264.0M | ||
| Q2 25 | $78.5M | $220.0M | ||
| Q1 25 | $92.7M | $75.0M | ||
| Q4 24 | $72.8M | $390.0M | ||
| Q3 24 | $66.7M | $141.0M | ||
| Q2 24 | $99.5M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $67.6M | $96.0M | ||
| Q3 25 | $14.8M | $218.0M | ||
| Q2 25 | $68.7M | $181.0M | ||
| Q1 25 | $82.7M | $43.0M | ||
| Q4 24 | $56.6M | $335.0M | ||
| Q3 24 | $47.4M | $99.0M | ||
| Q2 24 | $72.2M | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 6.4% | ||
| Q3 25 | 2.3% | 13.6% | ||
| Q2 25 | 10.4% | 11.4% | ||
| Q1 25 | 12.0% | 2.8% | ||
| Q4 24 | 7.7% | 21.0% | ||
| Q3 24 | 6.9% | 6.3% | ||
| Q2 24 | 9.8% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 3.0% | ||
| Q3 25 | 1.2% | 2.9% | ||
| Q2 25 | 1.5% | 2.4% | ||
| Q1 25 | 1.4% | 2.1% | ||
| Q4 24 | 2.2% | 3.5% | ||
| Q3 24 | 2.8% | 2.7% | ||
| Q2 24 | 3.7% | 2.0% |
| Q1 26 | 9.04× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.77× | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 9.54× | 0.39× | ||
| Q2 24 | 6.13× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMN
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
